U.S. patent number RE41,148 [Application Number 11/091,010] was granted by the patent office on 2010-02-23 for oral pulsed dose drug delivery system.
This patent grant is currently assigned to Shire Laboratories, Inc.. Invention is credited to Beth A. Burnside, Rong-Kun Chang, Richard A. Couch, Kimberly Fiske, Xiaodi Guo, Charlotte M. McGuinness, Edward M. Rudnic, Donald J. Treacy.
United States Patent |
RE41,148 |
Burnside , et al. |
February 23, 2010 |
**Please see images for:
( Certificate of Correction ) ** |
Oral pulsed dose drug delivery system
Abstract
A multiple pulsed dose drug delivery system for pharmaceutically
active amphetamine salts, comprising an immediate-release component
and an enteric delayed-release component wherein (1) the enteric
release coating has a defined minimum thickness and/or (2) there is
a protective layer between the pharmaceutically active amphetamine
salt and the enteric release coating and/or (3) there is a
protective layer over the enteric release coating. The product can
be composed of either one or a number of beads in a dosage form,
including either capsule, tablet, or sachet method for
administering the beads.
Inventors: |
Burnside; Beth A. (Bethesda,
MD), Guo; Xiaodi (Apex, NC), Fiske; Kimberly
(Downingtown, PA), Couch; Richard A. (Bryn Mawr, PA),
Treacy; Donald J. (Woodbine, MD), Chang; Rong-Kun
(Rockville, MD), Rudnic; Edward M. (North Potomac, MD),
McGuinness; Charlotte M. (Bethesda, MD) |
Assignee: |
Shire Laboratories, Inc.
(Rockville, MD)
|
Family
ID: |
22644775 |
Appl.
No.: |
11/091,010 |
Filed: |
October 20, 1999 |
PCT
Filed: |
October 20, 1999 |
PCT No.: |
PCT/US99/24554 |
371(c)(1),(2),(4) Date: |
July 19, 2001 |
PCT
Pub. No.: |
WO00/23055 |
PCT
Pub. Date: |
April 27, 2000 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
09176542 |
Oct 21, 1998 |
6322819 |
|
|
Reissue of: |
09807462 |
Jul 19, 2001 |
06605300 |
Aug 12, 2003 |
|
|
Current U.S.
Class: |
424/452; 514/649;
424/472; 424/471; 424/470; 424/469; 424/468; 424/458 |
Current CPC
Class: |
A61K
9/5078 (20130101); A61K 9/5047 (20130101); A61P
25/28 (20180101); A61P 25/00 (20180101); A61K
31/137 (20130101); A61K 9/5026 (20130101) |
Current International
Class: |
A61K
9/48 (20060101); A61K 31/135 (20060101); A61K
9/24 (20060101); A61K 9/26 (20060101) |
Field of
Search: |
;424/452,458,468-472,514,649 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
109438 |
|
Jan 1940 |
|
AU |
|
640 337 |
|
Mar 1995 |
|
EP |
|
59-082311 |
|
May 1984 |
|
JP |
|
03-148215 |
|
Jun 1991 |
|
JP |
|
07-061922 |
|
Mar 1995 |
|
JP |
|
09-249557 |
|
Sep 1997 |
|
JP |
|
09-267035 |
|
Oct 1997 |
|
JP |
|
10-081634 |
|
Mar 1998 |
|
JP |
|
WO87/00044 |
|
Jan 1987 |
|
WO |
|
WO90/09168 |
|
Aug 1990 |
|
WO |
|
WO-97/03673 |
|
Feb 1997 |
|
WO |
|
WO-98/14168 |
|
Apr 1998 |
|
WO |
|
WO-99/03471 |
|
Jan 1999 |
|
WO |
|
WO-00/25752 |
|
May 2000 |
|
WO |
|
WO-00/35450 |
|
Jun 2000 |
|
WO |
|
Other References
US 6,034,101, 3/2000, Gupta et al. (withdrawn) cited by other .
Complaint for Declaratory Judgment, Impax Laboratories, Inc. v.
Shire International Laboratories, Inc. (Civ. Action No. 05772) and
Exhibits attached thereto. cited by other .
Fukumori, Coating of Multiparticulates Using Polymeric Dispersions,
Multiparticulate Oral Drug Delivery (Swarbrick and Selassie eds.
1994), 79-110. cited by other .
Bodmeier et al., The Influence of Buffer Species and Strength on
Dittiazem HCl Release from Beads Coated with the Aqueous Cationic
Polmer Dispersions, Eudraglt RS, RL 30D, Pharmaceutical Research
vol. 13, No. 1, 1996, 52-56. cited by other .
Shire Laboratories Inc.'s Opposition to Barr Laboratories' Motion
to Amend Its Answers and Counterclaims, Sep. 15, 2004. cited by
other .
Chan, Materials Used for Effective Sustained-Release Products,
Proceedings of the International Symposium held on Jan. 29-31, 1987
(The Bombay College of Pharmacy 1988), 69-84. cited by other .
PDR Drug Information for Ritalin LA Capsules, Apr. (2004). cited by
other .
Greenhill et al., A Pharmacokinetic/Pharmacodynamic Study Comparing
a Single Morning Dose of Adderall to Twice-Daily Dosing in Children
with ADHD. J. Am. Acad. Adolesc. Psychiatry, 42:10, Oct. 2003.
cited by other .
Teva Notice letter: Feb. 21, 2005. cited by other .
Bauer, et al., Cellulose Acetate Phthalate (CAP) and Trimellitate
(CAT), Coated Pharmaceutical Dosage Forms (1998), 102-104. cited by
other .
Guidance for Industry: SUPAC-MR: Modified Release Solid Oral Dosage
Forms (1997). cited by other .
Treatise on Controlled Drug Delivery, pp. 285-299 (Agis Kydonieus
ed. 1992). cited by other .
Guidance for Industry: Extended Release Oral Dosage Forms:
Development, Evaluation, and Application of In Vitro/In Vivo
Correlations (1997). cited by other .
Wouessidjewe, Aqueous polymethacrylate Dispersions as Coating
Materials for Sustained and Enteric Release Systems, S.T.P. Pharma
Sciences 7(6) 469-475 (1997). cited by other .
Adderall XR Package Inset, Sep. (2004). cited by other .
Marcotte et al., Kinetics of Protein Diffusion from a
Poly(D,L-Lactide) Reservoir System, Journal of Pharmaceutical
Sciences, vol. 79, No. 5, May 1990. cited by other .
Guo Deposition Transcript, Jan. 24, 2005. cited by other .
Watano, et al., Evaluation of Aqueous Enteric Coated Granules
prepared by Moisture Control Method in Tumbling Fluidized Bed
Process, Chem. Pharm. Bull. 42(3) 663-667 (1994). cited by other
.
Schaffer Deposition Transcript, Aug. 17, 2005. cited by other .
Rambali, et al., Using experimental design to optimize the process
parameters in fluidized bed granulation on a semi-full scale,
International Journal of Pharmaceutics 220 (2001) 149-160. cited by
other .
Treacy Deposition Transcript, Aug. 31, 2004. cited by other .
Tulloch, et al., SL1381 (Adderall XR), a Two-component,
Extended-Release Formulation of Mixed Amphetamine Salts:
Bioavailability of Three Test formulatons and Comparison of Fasted,
Fed, and Sprinkled Administration, PHARMACOTHERAPY vol. 22, No. 11.
(2002), 1405-1415. cited by other .
Chang Deposition Transcript, Sep. 8, 2004. cited by other .
Edward Stempel, Prolonged Drug Action, HUSA's Pharmaceutical
Dispensing, Sixth Edition, 1966, 464, 481-485. cited by other .
McGuiness Deposition Transcript, Aug. 6, 2004. cited by other .
Remington's Pharmaceutical Sciences, RPS XIV, 1700-1714. cited by
other .
Fiske Deposition Transcript, Sep. 17, 2004. cited by other .
Vasilevska, et al., Preparation and Dissolution Characteristics of
Controlled Release Diltiazem Pellets, Drug Development and
Industrial Pharmacy, 18(15), 1649-1661 (1992). cited by other .
Opening Expert Report of Dr. Walter Chambliss and exhibits thereto,
Mar. 15, 2005. cited by other .
Agyilirah GA and Bauker SB, Polymers for Enteric Coating
Applications, Polymers for Controlled Drug Delivery (Peter J.
Tarcha ed. 1991) 39-66. cited by other .
Impax Laboratories, Inc.'s First Amended Answer and Affirmative
Defenses. cited by other .
Moller, Dissolution Testing of Delayed Release Preparations,
Proceedings of the International Symposium held on Jan. 29-31, 1987
(The Bombay College of Pharmacy 1988), 85-111. cited by other .
Impax Laboratories, Inc.'s Reply Memorandum in Support of the
Motion to Amend its Answer dated Mar. 18, 2005 and exhibits
thereto. cited by other .
Stevens, et al., Controlled, Multidose, Pharmacokinetic Evaluation
of Two Extended-Release Carbamazepine Formulations (Carbatrol and
Tegretol-XR), Journal of Pharmaceutical Sciences vol. 87, No. 12,
Dec. 1998, 1531-1534. cited by other .
Deposition transcript of Honorable Gerald J. Mossinghoff and
exhibits thereto. cited by other .
Physicians' Desk Reference: Adderall, 51st Ed. (1997). cited by
other .
Expert Report of Dr. Joseph R. Robinson and exhibits thereto, Feb.
28, 2005. cited by other .
Sriamornsak, et al., Development of sustained release theophylline
pellets coated with calcium pectinate, Journal of Controlled
Release 47 (1997) 221-232. cited by other .
Answering Expert Report of Dr. Alexander Klibanov, Apr. 25, 2005.
cited by other .
Sprowls' American Pharmacy: An Introduction to Pharmaceutical
Techniques and Dosage Forms, 7th Ed. (1974), 387-388. cited by
other .
Barr Laboratories' Objections and Responses to Plaintiff Shire
Laboratories Inc.'s Fifth Set of Interrogatories (No. 17). cited by
other .
Sheen, et al., Aqueous Film Coating Studies of Sustained Release
Nicotinic Acid Pellets: An In-Vitro Evaluation, Drug Development
and Industrial Pharmacy, 18(8), 851-860 (1992). cited by other
.
Barr Laboratories' Objections and Responses to Plaintiff Shire
Laboratories Inc.s' Fourth Set of Interrogatories (Nos. 15-16).
cited by other .
Barr Laboratories' Inc.'s Objections and Responses to Shire
laboratories Inc.'s Second Set of Interrogatories (Nos. 8-11).
cited by other .
Scheiffele, et al., Studies Comparing Kollicoat MAE 30 D with
Commercial Cellulose Derivatives for Enteric Coating on Caffeine
Cores, Drug Development and Industrial Pharmacy, 24(9), 807-818
(1998), 807-818. cited by other .
The United States Pharmacopeia 27, National Formulary 22 (2004) pp.
2302-2312. cited by other .
Expert Report of the Honorable Gerald J. Mossinghoff and exhibits
thereto, Mar. 16, 2005. cited by other .
The United States Pharmacopeia 23, National Formulary 18 (1995) pp.
1791-1799. cited by other .
Charles S.L. Chiao and Joseph R. Robinson, Sustained-Release Drug
Delivery Systems, Remington: The Science and Practice of Pharmacy,
Tenth Edition (1995) 1660-1675. cited by other .
The Merck Index: Amphetamine, 12th Ed., 620. cited by other .
Couch Deposition Transcript, Sep. 14, 2004. cited by other .
Shargel;. Pharmacokinetics of Oral Absorption, Applied
Biopharmaceutics & Pharmacokinetics. 5th Ed. (2005), 164-166.
cited by other .
American Chemical Society, Polymer Preprints, pp. 633-634, vol. 34,
No. 1, Mar. 1993. cited by other .
Remington: The Science and Practice of Pharmacy, Elutriation, 20th
Ed. (2000), 690. cited by other .
Harrington Deposition Transcript, Jul. 27, 2005. cited by other
.
Physicians' Desk Reference: Ritalin, 56th Ed. (2002). cited by
other .
Kennerly S. Patrick & John S. Markowitz, Pharmacology of
Methylphenidate, Amphetamine Enantiomers and Permoline in
Attention-Deficit Hyperactivity Disorder, Human Psychopharmacology,
vol. 12, 527-546 (1997). cited by other .
Physicians' Desk Reference: Adderall, 56th Ed. (2002). cited by
other .
Guidance for Industry: Food-Effect Bioavailability and Fed
Bioequivalence Studies (2002). cited by other .
McGraw-Hill Dictionary of Scientific and Technical Terms, 5th Ed.
(1994), 97, 972. cited by other .
McGough et al., Pharmacokinetics of SL1381 (Adderall XR), an
Extended-Release Formulation of Adderall, Journal of the American
Academy of Child & Adolescent Psychiatry, vol. 42, No. 6, Jun.
2003. cited by other .
Handbook of Pharmaceutical Excipients: Ethylcellulose,
Polymethacrylates, (4th ed. (2003), 237-240, 462-468. cited by
other .
Mathir et al., In vitro characterization of a controlled-release
chlorpheniramine maleate delivery system prepared by the
air-suspension technique, J. Microencapsulaton, vol. 14, No. 6,
743-751 (1997). cited by other .
R. Bianchini & C. Vecchio, Oral Controlled Release Optimization
of Pellets Prepared by Extrusion-Spheronization Processing, IL
Farmaco 44(6), 645-654, 1989. cited by other .
Chang et al., Preparation and Evaluation of Shellac Pseudolatex as
an Aqueous Enteric Coating Systems for Pellets, International
Journal of Pharmaceuticals, 60 (1990) 171-173, 1990. cited by other
.
Garnett et al., Pharmacokinetic Evaluation of Twice-Daily
Extended-Release Carbamazepine (CBZ) and Four-Times- Daily
Immediate-Release CBZ in Patients with Epilepsy, Epilepsia
39(3):274-279, 1998. cited by other .
Liu et al., Comparative Release of Phenylprepanolamine HCl from
Long-Acting Appetite Suppressant Product: Acutrim vs. Dexatrim,
Drug Development and Industrial Pharmacy, 10(10), 1639-1661 (1984).
cited by other .
Krowczynski & Brozyna, Extended-Release Dosage Forms, pp.
123-131 (1987). cited by other .
C. Lin et al., Bioavailability of d-pseudoephedrine and Azatadine
from a Repeat Action Tablet Formulation, J Int Med Res (1982),
122-125. cited by other .
Rosen et al., Absorption and Excretion of Radioactively Tagged
Dextroamphetamine Sulfate from a Sustained-Release Preparation,
Jama, vol. 194, No. 11, Dec. 13, 1965. 145-147. cited by other
.
C. Lin et al., Compartive Bioavailability of d-pseudoephedrine from
a Conventional d-pseudoephedrine Sulfate Tablet and from a Repeat
Action Tablet, J Int Med Res (1982) 10, 126-128. cited by other
.
Pelham et al., A Comparison of Morning-Only and Morning/Late
Afternoon Adderall to Morning-Only, Twice-Daily, and Three
Times-Daily Methylphenidate in Children with
Attention-Deficit/Hyperactivity Disorder, Pediatrics, vol. 104, No.
6, Dec. 1999. cited by other .
Serajuddin, et al., Selection of Solid Dosage Form Composition
through Drug-Excipient Compatibility Testing, Journal of
Pharmaceutical Sciences vol. 88, No. 7, Jul. 1999, 696-704. cited
by other .
Slattum, et al., Comparison of Methods for the Assessment of
Central Nervous System Stimulant Response after Dextroamphetamine
Adminstration to Healthy Male Volunteers, J. Clin Pharmacol 1996;
36: 1039-1050. cited by other .
Lin & Cheng, In-vitro Dissolution Behaviour of Spansule-type
Micropellets Prepared by Pan Coating Method, Pharm. Ind. 51 No. 5
(1989). cited by other .
Remington's Pharmaceutical Sciences, Fifteenth Edition (1975)
1624-1625. cited by other .
Ansel et al., Rate Controlled Dosage Forms and Drug Delivery
Systems, Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th
Ed. (1995), 213-222. cited by other .
Chan, New Polymers for Controlled Release Products, Controlled
Release Dosage Forms Proceedings of the International Symposium
held on Jan. 29-31, 1987 (The Bombay College of Pharmacy 1988)
59-111. cited by other .
Leopold & Eikeler, Eudragit E as Coating Material for the
pH-Controlled Drug Release in the Topical Treatment of Inflammatory
Bowel Disease (IBD), Journal of Drug Targeting, 1998, vol. 6, No.
2, pp. 85-94. cited by other .
Jarowski, The Pharmaceutical Pilot Plant, Pharmaceutical Dosage
Forms: Tablets, vol. 3, 2nd Ed. (1990), 303-367. cited by other
.
Remington: The Science and Practice of Pharmacy, Basic
Pharmacokinetics, 16th Ed. (1980), 693. cited by other .
Rong-Kun Chang and Joseph R. Robinson, Sustained Drug Release from
Tablets and Particles Through Coating, Pharmaceutical Dosage Forms:
Tablets (Marcel Dekker, Inc. 1990), 199-302. cited by other .
Hall HS and Pondell RE, Controlled Release Technologies: Methods,
Theory, and Applications, pp. 133-154 (Agis F. Kydonieus ed. 1980).
cited by other .
Porter and Bruno Coating of Pharmaceutical Solid-Dosage Forms,
77-160. cited by other .
Barr Laboratores' Memorandum In Support of its Motion to Amend its
Pleadings and exhibits thereto. cited by other .
Answering Expert Report of Robert Langer, Apr. 25, 2005. cited by
other .
Hans-Martin Klein & Rolf W. Gunther, Double Contrast Small
Bowel Follow-Through with an Acid-Resistant Effervescent Agent,
Investigative Radiology vol. 28, Jul. 1993. cited by other .
Opening Expert Report of Dr. Michael Mayersohn and exhibits
thereto, Mar. 12, 2005. cited by other .
Rudnic Deposition Transcript, Jul. 28, 2004. cited by other .
Burnside Deposition Transcript, Feb. 2, 2005. cited by other .
Kao et al., Lag Time Method to Delay Drug Release to Various Sites
in the Gastrointestinal Tract, Journal of Controlled Release
44(1997) 263-270. cited by other .
Freedom of Information Request Results for--Dexadrine (SmithKline
Beecham): May 20, 1976 Disclosable Approval Information. cited by
other .
Teva Notice letter: Jun. 1, 2005. cited by other .
Prescribing Information: Dexedrine, brand of dextroamphetamine
sulfate (2001). cited by other .
Husson et al., Influence of Size Polydispersity on Drug Release
from Coated Pellets, International Journal of Pharmaceutics, 86
(1992) 113-121, 1992. cited by other .
Rong-Kun Chang et al., Formulation Approaches for Oral Pulsatile
Drug Delivery, American Pharmaceutical Review. cited by other .
Kiriyama et al., The Bioavailability of Oral Dosage Forms of a New
HIV-1 Protease Inhibitor, KNI-272, in Beagle Dogs, Biopharmaceutics
& Drug Disposition, vol. 17 125-134 (1996). cited by other
.
Klaus Lehmann, Coating of Multiparticulates Using Polymeric
Solutions, Multiparticulate Oral Drug Delivery (Swarbrick and
Sellassie ed., 1994). cited by other .
Goodhart et al., An Evaluation of Aqueous Film-forming Dispersions
for Controlled Release, Pharmaceutical Technology, Apr. 1984. cited
by other .
Rosen, et al., Absorption and Excretion of Radioactively Tagged
Dextroamphetamine Sulfate From a Sustained-Release Preparation,
Journal of the American Medical Association, Dec. 13, 1965, vol.
194, No. 11, 1203-1205. cited by other .
Leon Lachman, Herbert A. Lieberman, Joseph L. Kanig, The Theory and
Practice of Industrial Pharmacy, Second Edition (1976) 371-373.
cited by other .
Wesdyk, et al., Factors affecting differences in film thickness of
beads coated in fluidized bed units, International Journal of
Pharmaceutics, 93 101-109, (1993). cited by other .
Daynes, Treatment of Noctural Enuresis with Enteric-Coated
Amphetamine, The Practitioner, No. 1037, vol. 173, Nov. 1954. cited
by other .
Physicians' Desk Reference: Dexedrine 56th Ed. (2002). cited by
other .
The United States Pharmacopeia 26, National Formulary 21 (2003) pp.
2157-2165. cited by other .
Barr Laboratories' Supplemental Objections and Responses to
Plaintiff Shire Laboratories Inc.'s Third Set of Interrogatories
(Nos. 12-14 Redacted). cited by other .
Rong-Kun Chang, A Comparison of Rheological and Enteric Properties
among Organic Solutions, Ammonium Salt Aqueous Solutions, and Latex
Systems of Some Enteric Polymers, Pharmaceutical Technology, Oct.
1990. cited by other .
Guo Deposition Transcript, Jul. 26, 2004. cited by other .
Chang Deposition Transcript, Jan. 20, 2005. cited by other .
Holt, Bioequivalence Studies of Ketoprofen: Product formulation,
Pharmacokinetics, Deconvolution, and In Vitro - In Vivo
correlations, Thesis submitted to Oregon State University, Aug.
(1997). cited by other .
Cody et al., Amphetamine Enantiomer Excretion Profile Following
Administration of Adderall, Journal of Analytical Toxicology, vol.
2, Oct. 2003, 485-492. cited by other .
Ishibashi et al., Design and Evaluatin of a New Capsule-type Dosage
Form for Colon-Targeted Delivery of Drugs, International Journal of
Pharmaceutics 168, (1998) 31-40, 1998. cited by other .
Harris et al., Aqueous Polymeric Coating for Modified-Release
Pellets, Acqueous Polymeric Coating for Pharmaceutical Dosage Forms
(McGinity ed., 1989). cited by other .
J. Sjogren, Controlled release oral formulation technology, Rate
Control in Drug Therapy, (1985) 38-47. cited by other .
Burns et al., A Study of Enteric-coated Liquid-filled Hard Gelatin
Capsules with Biphasic Release Characteristics, International
Journal of Pharmaceutics 110 (1994) 291-296. cited by other .
The Merck Index: Amphetamine, 13th Ed. (2001), 97, 1089. cited by
other .
Impax Laboratories, Inc.'s First Supplemental Responses to Shire
Laboratories Inc.'s First Set of Interrogatories (Nos. 11-12).
cited by other .
Burnside Deposition Transcript, Feb. 3, 2005. cited by other .
Brown et al., Plasma Levels of d-Amphetamine in Hyperactive
Children, Psychopharmacology 62, 133-140, 1979. cited by other
.
Mehta et al., Evaluation of Fluid-bed Processes for Enteric Coating
Systems, Pharmaceutical Technology, Apr. 1986. cited by other .
Handbook of Pharmaceutical Excipients: Plymethacrylates, (2nd ed.
1994), 361-366. cited by other .
Impax Laboratories, Inc.'s Memorandum in Support of the Motion to
Amend its Answer dated Feb. 25, 2005 and exhibits thereto. cited by
other .
Brauer et al., Acute Tolerance to Subjective but not Cardiovascular
Effects of d-Amphetamine in Normal, Healthy Men, Journal of
Clinical Psychopharmacology, 1996; 16(1):72-76. cited by other
.
Glatt, The World of the Fluid Bed, Fluid Bed Systemsm, 1-19. cited
by other .
Brown et al., Behavior and Motor Activity Response in Hyperactive
Children and Plasma Amphetamine Levels Following a Sustained
Release Preparation, Journal of the American Academy of Child
Psychiatry, 19:225-239, 1980. cited by other .
Office Action mailed Mar. 2, 2005 in European Patent Aplication No.
99 970594.0-2123. cited by other .
Angrist et al., Early Pharmacokinetics and Clinical Effects of Oral
D-Amphetamine in Normal Subjects, Biol. Psychiatry 1987, 22:
1357-1368. cited by other .
Court Docket for Shire Laboratories v. Teva Pharmaceutical
Industries Ltd., Case No. 2:06-cv-00952-SD, Jan. 8, 2007. cited by
other .
Complaint in Shire Laboratories v. Teva Pharmaceutical Industries
Ltd., and exhibits thereto, Case No. 2:06-cv-00952-SD, Mar. 2,
2006. cited by other .
Answer and Counterclaims in Shire Laboratories v. Teva
Pharmaceutical Industries Ltd., Case No. 2:06-cv-00952-SD, Jul. 24,
2006. cited by other .
Reply to Counterclaims in Shire Laboratories v Teva Pharmaceutical
Industries Ltd., Case No. 2:06-cv-00952-SD, Aug. 16, 2006. cited by
other .
Defendants' Response to Plaintiff Shire's First Set of
Interrogatories (1-12) in Shire Labatories v. Teva Pharmaceutical
Industries Ltd., Case No. 2:06-cv-00952-SD, Sep. 20, 2006. cited by
other .
Defendants' Responses to Plaintiff's First Set of Request for the
Production of Documents and Things (1-70) in Shire Laboratories v.
Teva Pharmaceutical Industries Ltd., Case No. 2:06-cv-00952-SD,
Oct. 4, 2006. cited by other .
Plaintiff's Response to Defendants' First Set of Interrogatories in
Shire Labatories v. Teva Pharmaceutical Industries Ltd., Case No.
2:06-cv-00952-SD, Oct. 11, 2006. cited by other .
Plaintiff's Response to Defendants' First Set of Production
Requests in Shire Laboratories v. Teva Pharmaceutical Industries
Ltd., Case No. 2:06-cv-00952-SD, Oct. 11, 2006. cited by other
.
Defendants' Responses to Plaintiff's Second Set of Requests for the
Production of Documents and Things (71-80) in Shire Laboratories v.
Teva Pharmaceuticals Industries Ltd., Case No. 2:06-cv-00952-SD,
Nov. 8, 2006. cited by other .
Defendants' Responses to Plaintiff Shire's Second Set of
Interrogatories (No. 13) in Shire Laboratories v. Teva
Pharmaceuticals Industries Ltd., Case No. 2:06-cv-00952-SD, Nov. 8,
2006. cited by other .
Petition Under Section 8 and exhibits thereto, submitted to the
Canadian Patent Office on Dec. 4, 2006. cited by other .
Exh. 3, Excerpts from the Deposition Transcript of Richard Chang,
dated Sep. 8, 2004. cited by other .
Exh. 4, Excerpts from the Deposition Transcript of Richard A.
Couch, dated Sep. 14, 2004. cited by other .
Exh. 5, Excerpts from the Deposition Transcript of Kimberly Fiske,
dated Sep. 17, 2004. cited by other .
Exh. 6, Excerpts from the Deposition Transcript of Charlotte M.
McGuiness, dated Aug. 6, 2004. cited by other .
Exh. 7, Excerpts from the Deposition Transcript of Beth Burnside,
dated Feb. 2, 2005. cited by other .
Exh. 8, Excerpts from the Deposition Transcript of Donald John
Treacy, Jr., dated Aug. 31, 2004. cited by other .
Exh. 9, Excerpts from the Deposition Transcript of Beth Burnside,
dated Feb. 3, 2005. cited by other .
Exh. 10, Excerpts from the Deposition Transcript of Xiaodi Guo,
dated Jan. 24, 2005. cited by other .
Exh. 11, Excerpts from the Deposition Transcript of Xiaodi Guo,
dated Jul. 26, 2004. cited by other .
Exh. 12, Excerpts from the Deposition Transcript of Edward Rudnic,
dated Jul. 28, 2004. cited by other .
Exh. 13, Excerpts from the Deposition Transcript of Richard
Rong-Kun Chang, dated Jan. 20, 2005. cited by other .
Exh. 14, Impax Laboratories Answer And Affirmative Defenses Shire
Laboratories, Inc. v. Impax Laboratories, Inc., Civil Action No.
03-CV-01164-GMS. cited by other .
Exh. 15, Barr Laboratories' Amended Answer, Affirmative Defenses,
And Counterclaims, Shire Laboratories, Inc. v. Barr Laboratories,
Inc., Civil Action No. 03-CV-6632-PKC. cited by other .
Exh. 16, Barr Laboratories' Amended Answer, Affirmative Defenses
And Counterclaims, Shire Laboratories, Inc. v. Barr Laboratories,
Inc., Civil Action No. 03-CV-1219-PKC. cited by other .
Exh. 17, Reply to Barr Laboratories Inc.'s Amended Answer,
Affirmative Defenses And Counterclaims, Shire Laboratories, Inc. v.
Barr Laboratories, Inc., Civil Action No. 03-CV-6632-PKC. cited by
other .
Exh. 18, Civil Docket For Case #: 1:03-cv-01164-GMS, Shire
Laboratories, Inc. v. Impax Laboratories, Inc., Civil Action No.
03-CV-01164-GMS. cited by other .
Exh. 19, Civil Docket For Case #: 1:05-cv-00020-GMS, Shire
Laboratories, Inc. v. Impax Laboratories, Inc., Civil Action No.
05-20-GMS. cited by other .
Exh. 20, Civil Docket For Case #: 1:03-cv-06632-VM-DFE, Shire
Laboratories, Inc. v. Barr Laboratories, Inc., Civil Action No.
03-CV-6632-PKC. cited by other .
Exh. 21, Civil Docket For Case #: 1:03-cv-01219-PKC-DFE, Shire
Laboratories, Inc. v. Barr Laboratories, Inc., Civil Action No.
03-CV-1219-PKC. cited by other .
Exh. 25, Barr Laboratories, Inc.'s '819 Notification Pursuant to
.sctn. 505(j)(B)(ii) of the Federal Food, Drug and Cosmetic Act (21
U.S.C. .sctn. 355(j)(2)(B)(ii) and 21 C.F.R. .sctn. 314.95. cited
by other .
Exh. 26, Barr Laboratories, Inc.'s '300 Notification Pursuant to
.sctn. 505(j)(2)(B)(ii) of the Federal Food, Drug and Cosmetic Act
(21 U.S.C. .sctn. 355(j)(2)(B)(ii) and 21 C.F.R. .sctn. 314.95).
cited by other .
Exh. 27, Order Construing The Terms Of U.S. Patent Nos. 6,322,819
and 6,605,300, Shire Laboratories, Inc. v. Impax Laboratories,
Inc., Civil Action No. 03-CV-01164-GMS. cited by other .
Gazzaniga, et al., S.T.P. Pharma Sciences, vol. 5, No. 1, gs. 83-88
(1995), Time dependent oral delivery for colon targeting. cited by
examiner .
Modern Pharmaceutics, Banker, et al., eds., Marcel Dekker, Inc.,
New York, p. 350 (1996). cited by examiner .
Walia, et al., Pharm. Dev. Tech., vol. 3, No. 1, pp. 103-113
(1998), Preliminary Evaluation of an Aqueous Wax Emulsion for
Controlled-Release Coating. cited by examiner .
Wilding et al., Pharmaceutical Research, vol. 9, No. 5, pp. 654-657
(1992), Gastrointestinal Transit and Systemic Absorption of
Captopil from Pulsed-Release Formulation. cited by examiner .
Xu, et al., Pharmaceutical Research, vol. 10, No. 8, pp. 1144-1152
(1993), Programmable Drug Delivery from an Erodible Association
Polymer System. cited by examiner .
Conte, et al., Biomaterials, vol. 14, No. 13, pp. 1017-1023 (1993),
Press-coated tablets for time-programmed release of drugs. cited by
examiner .
Gazzaniga, et al., Eur. J. Pharm. Biopharm., vol. 40, No. 4, pp.
246-250 (1994), Oral Chronotopic Drug Delivery System: Achievement
of Time and/or Site Specificity. cited by examiner .
Pozzi, et al., J. Controlled Release, vol. 31, pp. 99-108 (1994),
The Time Clock System: a new oral dosage form for fast and complete
release of drug after a predetermined lag time. cited by examiner
.
Snire Laboratory Inc's Complaint against Barr Laboratories based on
Parent U.S. patent 6,322,815 in U S District Court for the Southern
District of New York (Case No. 03-CV-1219(VM)(DFE)) 2003. cited by
examiner .
Barr Laboratories' Answer. Affirmative Defenses and Counterclaim in
Case No. 03-CV-1219(VM)(DFE) (S D N Y ) 2003. cited by examiner
.
Barr's Paragraph IV Certification against Parent U S Patent
6,322,819 on Jan. 14, 2003. cited by examiner .
Transcript of Richard A. Couch 30(b)(6) Deposition in Shire LLC vs.
Sandoz Inc. in the United States District Court for the District of
Colorado, Dec. 14, 2007. cited by other .
Transcript of Beth A. Burnside Deposition in Shire LLC vs. Sandoz
Inc. in the United States District Court for the District of
Colorado, Case No. 07-CV-00197-EWN-CBS, Nov. 30, 2007. cited by
other .
Transcript of Kimberly Fiske Farrand Deposition in Shire, LLC v.
Sandoz, Inc. in Shire, LLC v. Sandoz, Inc. in the United States
District Court for the District of Colorado, Dec. 4, 2007. cited by
other .
Defendant Sandoz, Inc.'s Answers and Objections to Plaintiff Shire
LLC's Interrogatories (Nos. 1-9), in the United States District
Court for the District of Colorado, Case No. 07-CV-00197-EWN-CBS,
Jun. 18, 2007. cited by other .
Defendant Sandoz, Inc.'s Answers and Objections to Plaintiff Shire
LLC's Second Set of Interrogatories (Nos. 10-19), in the United
States District Court for the District of Colorado, Case No.
07-CV-00197-EWN-CBS, Nov. 20, 2007. cited by other .
Defendant Sandoz, Inc.'s Answers and Objections to Plaintiff Shire
LLC's Third Set of Interrogatories (Nos. 20-25) and Supplement to
Answers to Interrogatories 8 and 9, in the United States District
Court for the District of Colorado, Case No. 07-CV-00197-EWN-CBS,
Dec. 10, 2007. cited by other .
Expert Report of Arthur J. Steiner in Shire LLC v. Colony
Pharmaceuticals, Inc., in the United States District Court for the
District of Maryland, Case No. 1:07-cv-00718, Dec. 20, 2007. cited
by other .
Supplemental Expert Report of Harry G. Brittain, PhD, FRSC in Shire
LLC v. Colony Pharaceuticals, Inc., in the United States District
Court of the District of Maryland, Case No. 1:07-cv-00718, Feb. 15,
2008. cited by other .
Ozturk et al., "Kinetics of Release from Enteric-Coated Tablets,"
Pharmaceutical Research, 1988;5:550-565. cited by other .
Ghebre-Sellassie et al., "Evaluation of acrylic-based
modified-release film coatings," International Journal of
Pharmaceutics, 1987;37:211-218. cited by other .
Order and Memorandum Denying Colony's Motion for Partial Summary
Judgment of Noninfringement of the '819 and '300 Patents in Shire
LLC v. Colony Pharmaceuticals, Inc., in the United States District
Court for the District of Maryland, Case No. CCB-07-718, Jan. 2,
2008. cited by other .
Plaintiff Shire LLC's Responses to Interrogatories Nos. 1-13 in
Shire LLC v. Colony Parmaceuticals, Inc., in the United States
District Court for the District of Maryland, Case No.
1:07-cv-00718-CCB, Jun. 6, 2007. cited by other .
Transcript of Richard A. Couch Deposition in Shire LLC v. Colony
Pharmaceuticals, Inc. in the United States District Court for the
District of Maryland, Case No. 1:07-cv-00718-CCB, Nov. 15, 2007.
cited by other .
Transcript of Beth A. Burnside Deposition in Shire LLC v. Colony
Pharmaceuticals, in the United States District Court for the
District of Maryland, Case No. 1:07-cv-00718-CCB, Nov. 9, 2007.
cited by other .
Transcript of Richard Rong-Kun Chang in Shire LLC v. Colony
Pharmaceuticals, Inc. in the United States District Court for the
District of Maryland, Case No. 1:07-cv-00718-CCB, Nov. 20, 2007.
cited by other .
Judgment and Order of Permanent Injunction in Shire LLC v. Teva
Pharmaceutical Industries Ltd. in the United States District Court
for the Eastern District of Pennsylvania, Civil Action No.
06-952-SD, Mar. 6, 2008. cited by other .
Colony Pharmaceuticals, Inc.'s Responses to Plaintiff Shire LLC's
Interrogatories (Nos. 1-7) in Shire LLC v. Colony Pharmaceuticals,
Inc. in the United States District Court for the District of
Maryland, Civil Action No. 1:07-cv-00718-CCB, May 29, 2007. cited
by other .
Judgment and Order of Permanaent Injunction in Shire LLC v. Colony
Pharmaceuticals, Inc. in the United States District Court for the
District of Maryland, Civil Action No. 1:07-cv-00718-CCB, Apr. 14,
2008. cited by other .
Supplemental Expert Report of Vladimir P. Torchilin, Ph.D., D.Sc.
Regarding the Invalidity of U.S. Patent No. 6,605,300 in Shire LLC
v. Colony Pharmaceuticals, Inc. in the United States District Court
for the District of Maryland, Civil Action No. 1:07-cv-00718-CCB
and exhibits thereto, Feb. 15, 2008. cited by other .
Plaintiff Shire LLC's Supplemental Responses to Interrogatory Nos.
1-5, 8, 9, & 12 in Shire LLC v. Colony Pharmaceuticals, Inc. in
the United States District Court for the District of Maryland,
Civil Action No. 1:07-cv-00718-CCB, Aug. 22, 2007. cited by other
.
Colony Pharmaceuticals, Inc.'s Amended Responses to Plaintiff Shire
LLC's Interrogatories (Nos. 1-7) in Shire LLC v. Colony
Pharmaceuticals, Inc. in the United States District Court for the
District of Maryland, Civil Action No. 1:07-cv-00718-CCB, Jun. 5,
2007. cited by other .
Colony Pharmaceuticals, Inc.'s Supplemental Responses to Plaintiff
Shire LLC's Interrogatory Nos. 2-4 and 7 in Shire LLC v. Colony
Pharmaceuticals, Inc. in the United States District Court for the
District of Maryland, Civil Action No. 1:07-cv-00718-CCB, Sep. 5,
2007. cited by other .
Actavis Elizabeth LLC's Supplemental Responses to Plaintiff Shire
LLC's Interrogatory Nos. 5 and 6 in Shire LLC v. Colony
Pharmaceuticals, Inc. in the United States District Court for the
District of Maryland, Civil Action No. 1:07-cv-00718-CCB, Nov. 14,
2007. cited by other .
Expert Report of Harry G. Brittain, Ph.D. FRSC in Shire LLC v.
Colony Pharmaceuticals, Inc. in the United States District Court
for the District of Maryland, Civil Action No. 1:07-cv-00718-CCB
and exhibits thereto, Dec. 19, 2007. cited by other .
Expert Report of Vladimir P. Torchilin, Ph.D., D.Sc. Regarding the
Invalidity of U.S. patent No. 6,605,300 in Shire LLC v. Colony
Pharmaceuticals, Inc. in the United States District Court for the
District of Maryland, Civil Action No. 1:07-cv-00718-CCB and
exhibits thereto, Dec. 20, 2007. cited by other .
Corrected Expert Report of Vladimir P. Torchilin, Ph.D. D.Sc.
Regarding the Invalidity of U.S. Patent No. 6,605,300 in Shire LLC
v. Colony Pharmaceuticals, Inc. in the United States District Court
for the District of Maryland, Civil Action No. 1:07-cv-00718-CCB,
Dec. 21, 2007. cited by other .
Memorandum of Law in Support of Defendants' Motion for
Clarification or, in the Alternative for Reconsideration in Shire
LLC v. Colony Pharmaceuticals, Inc. in the United States District
Court for the District of Maryland, Civil Action No.
1:07-cv-00718-CCB, Jan. 16, 2008. cited by other .
Memorandum of Law in Support of Defendants' Motion for
Certification for Immediate Appeal Pursuant to 28 U.S.C. .sctn.
1292(b) in Shire LLC v. Colony Pharmaceuticals, Inc. in the United
States District Court for the District of Maryland, Civil Action
No. 1:07-cv-00718-CCB, Jan. 17, 2008. cited by other .
Judgment and Order of Permanent Injunction in Shire Laboratories,
Inc. v. Andrx Pharmaceuticals, LLC in the United States District
Court for the Southern District of Florida, Miami Division, Case
No. 07-22201-Civ-Cooke/Brown, Nov. 19, 2007. cited by other .
Judgement and Order of Permanent Injunction in Shire LLC v. Teva
Pharmaceutical in the United States District Court for the Eastern
District of Pennsylvania, Civil Action No. 06-952-SD, Mar. 6, 2008.
cited by other .
Office Action issued Jul. 24, 2008 in U.S. Appl. No. 11/091,011.
cited by other .
Neville et al., Disintegration of Dextran Sulfate Tablet Products:
Effect of Physicochemical Properties, Drug Development and
Industrial Pharmacy, New York, NY, vol. 18, No. 19, Jan. 1, 1992
(Jan. 1, 1992), pp. 2069-2079, XP009092848, ISSN: 0363-9045. cited
by other .
Patrick et al., Pharmacology of Methylphenidate, Amphetamine
Enantiomers and pemoline in Attention-Deficit Hyperactivity
Disorder, Human Psychopharmacology, vol. 12, pp. 527-546 (1997).
cited by other .
Chaumeil et al., Enrobages gastro-resistants a l'acetophtalate de
cellulose, Annales Pharmaceutiques Francaises, 1973, No. 5, pp.
375-384. cited by other .
U.S. Appl. No. 11/091,011, filed Apr. 7, 2009 Non-Final Office
Action. cited by other .
Office Action dated Dec. 6, 2007 in U.S. Appl. No. 11/091,011.
cited by other .
Judgment and Order of Permanent in Shire Laboratories, Inc. and
Shire, LLC v. Andrx Pharmaceuticals, LLC, et al., In the United
States District Court for the Southern District of Florida, Miami
Division, Case No. 07-22201-CIV-Cooke/Brown, Nov. 19, 2007. cited
by other .
Answer and Counterclaims in Shire Laboratories, Inc. and Shire, LLC
v. Andrx Pharmaceuticals, LLC, et al., in the United States
District Court for the Southern District of Florida, Case No.
07-22201-CIV-Cooke/Brown, Aug. 31, 2007. cited by other .
Plaintiffs Shire Laboratories, Inc.'s and Shire LLC's Reply to
Defendant Andrx Pharmaceuticals, LLC's Counterclaims in Shire
Laboratories, Inc. and Shire, LLC v.Andrx Pharmaceuticals, LLC, et
al., in the United States District Court for the Southern District
of Florida, Miami Division, Case No. 07-22201-CIV-Cooke/Brown, Sep.
24, 2007. cited by other .
Second Amended Complaint for Patent Infringement and Declaratory
Relief in Shire Laboratories, Inc. and Shire, LLC v. Andrx
Pharmaceuticals, LLC, et al., in the United States District Court
for the Southern District of Florida, Miami Division, Case No.
07-22201-CIV-Cooke/Brown, Nov. 15, 2007. cited by other .
Wigal, et al., Evaluation of Infividual Subjects in the Analog
Clasroom Setting; II. Effects of Dose of Amphetamine (Adderall),
Psychopharmacology Bulletin, vol. 34, No. 4, pp. 833-838, 1998.
cited by other .
Office Action dated Jun. 22, 2007 in Japanese patent Application
No. 2000-576830. cited by other .
Office Action dated Jun. 22, 2007 in U.S. Appl. No. 11/091,011.
cited by other .
Amendment dated Sep. 24, 2007 in U.S. Appl. No. 11/091,011. cited
by other.
|
Primary Examiner: Wang; Shengjun
Attorney, Agent or Firm: McDermott Will & Emery LLP
Parent Case Text
This application is a 371 of PCT/US99/24554 filed Oct. 20, 1999,
which is continuation-in-part of application Ser. No. 09/176,542,
filed Oct. 21, 1998, now U.S. Pat. No. 6,322,819 the contents of
which are incorporated herein by reference.
This invention pertains to a multiple dosage form delivery system
comprising one or more amphetamine salts for administering the
amphetamine salts to a recipient.
Claims
What is claimed is:
1. A pharmaceutical formulation for delivery of a mixture of
amphetamine base salts effective to treat ADHD in a human patient
comprising: an immediate release dosage form that provides
immediate release upon oral administration to said patient; a
delayed enteric release dosage form that provides delayed release
upon oral administration to said patient; and a pharmaceutically
acceptable carrier; wherein said amphetamine base salts comprise
dextroamphetamine sulfate, dextroamphetamine saccharate,
amphetamine aspartate monohydrate and amphetamine sulfate; wherein
said pharmaceutical formulation is sufficient to maintain an
effective level of amphetamine base salts in the patient over the
course of at least 8 hours without further administration of
amphetamine base salt, and the peak plasma concentration of
amphetamine base salts reached after release of said delayed
enteric release dosage form exceeds the peak plasma concentration
previously reached after release of said immediate release dosage
form; and wherein said pharmaceutical formulation, when containing
about a total dose of 20 mg, will produce in a human individual a
plasma concentration versus time curve (ng/ml versus hours) having
an area under the curve (AUC) of about 467 to about 714 ng
hr/ml.
2. A formulation of claim 1 wherein said plasma concentration curve
has a maximum concentration (C.sub.max) of about 22.5 to about 40
ng/ml for about a total dose of 20 mg.
3. A formulation of claim 2 wherein the time after said oral
administration to reach said C.sub.max value is about 7 to about 10
hours.
4. A formulation of claim 1 wherein the time after said oral
administration to reach maximum concentration of said plasma
concentration curve is about 7 to about 10 hours.
5. A formulation of claim 2, 3 or 4 wherein said AUC is about 714
ng hr/ml.
6. A formulation of claim 3 wherein said AUC is about 714 ng hr/ml,
the time after said oral administration to reach said C.sub.max
value is about 7 hours and C.sub.max is about 40 ng/ml.
7. A formulation of claim 2 wherein C.sub.max is about 40
ng/ml.
8. A formulation of claim 3 or 4 wherein said time is about 7
hours.
9. A formulation of one of claims 1-4, 6 or 7 wherein said salts
are contained in about equal amounts within each of said dosage
forms.
10. A formulation of one of claims 1-4, 6 or 7 wherein said delayed
enteric release dosage form comprises a coating of a thickness of
.[.at least.]. .Iadd.greater than .Iaddend.20 .mu.m which comprises
dried about 30% (dry substance) aqueous dispersion of an anionic
copolymer based on methacrylic acid and acrylic acid ethyl ester,
said coating being soluble at a pH of about 5.5 upwards.
11. A formulation of claim 10 wherein said thickness is at least 25
.mu.m.
12. A pharmaceutical formulation for delivery of a mixture of
amphetamine base salts effective to treat ADHD in a human patient
comprising: an immediate release dosage form that provides
immediate release upon oral administration to said patient; a
delayed enteric release dosage form that provides delayed release
upon oral administration to said patient, wherein said enteric
release dosage form comprises a coating of a thickness of .[.at
least.]. .Iadd.greater than .Iaddend.20 .mu.m which comprises dried
aqueous dispersion of an anionic copolymer based on methacrylic
acid and acrylic acid ethyl ester, said coating being soluble at a
pH of about 5.5 upwards; and a pharmaceutically acceptable carrier;
wherein said amphetamine base salts comprise dextroamphetamine
sulfate, dextroamphetamine saccharate, amphetamine aspartate
monohydrate and amphetamine sulfate; wherein said pharmaceutical
formulation is sufficient to maintain an effective level of
amphetamine base salts in the patient over the course of at least 8
hours without further administration of amphetamine base salt, and
the peak plasma concentration of amphetamine base salts reached
after release of said delayed enteric release dosage form exceeds
the peak plasma concentration of said salts previously reached
after release of said immediate release dosage form.
13. A formulation of claim 12 wherein said thickness is at least 25
.mu.m.
14. A formulation of claim 12, wherein said dried aqueous
dispersion of an anionic copolymer is a dried about 30% (dry
substance) aqueous dispersion of an anionic copolymer.
15. A formulation of claim 1 formulated for a total dose of 20
mg.
16. A formulation of claim 2 formulated for a total dose of 20
mg.
17. A formulation of claim 1 formulated for a total dose different
from about 20 mg and having an AUC proportional to said 20 mg
AUC.
18. A formulation of claim 2 formulated for a total dose different
from about 20 mg and having a C.sub.max proportional to said 20 mg
C.sub.max.
.Iadd.19. The pharmaceutical formulation of claim 1, wherein the
delayed release is pH independent..Iaddend.
.Iadd.20. The pharmaceutical formulation of claim 1, which further
comprises a protective coating layer..Iaddend.
Description
BACKGROUND OF THE INVENTION
Traditionally, drug delivery systems have focused on
constant/sustained drug output with the objective of minimizing
peaks and valleys of drug concentrations in the body to optimize
drug efficacy and to reduce adverse effects. A reduced dosing
frequency and improved patient compliance can also be expected for
the controlled/sustained release drug delivery systems, compared to
immediate release preparations. However, for certain drugs,
sustained release delivery is not suitable and is affected by the
following factors: First pass metabolism: Some drugs, such as
.beta. blockers, .beta.-estradiol, and salicylamide, undergo
extensive first pass metabolism and require fast drug input to
saturate metabolizing enzymes in order to minimize pre-systemic
metabolism. Thus, a constant/sustained oral method of delivery
would result in reduced oral bio-availability. Biological
tolerance: Continuous release drug plasma profiles are often
accompanied by a decline in the pharmacotherapeutic effect of the
drug, e.g., biological tolerance of transdermal nitroglycerin.
Chronopharmacology and circadian rhythms: Circadian rhythms in
certain physiological functions are well established. It has been
recognized that many symptoms and onset of disease occur during
specific time periods of the 24 hour day, e.g., asthma and angina
pectoris attacks are most frequently in the morning hours (1,2).
Local therapeutic need: For the treatment of local disorders such
as inflammatory bowel disease, the delivery of compounds to the
site of inflammation with no loss due to absorption in the small
intestine is highly desirable to achieve the therapeutic effect and
to minimize side effects. Gastric irritation or drug instability in
gastric fluid: For compounds with gastric irritation or chemical
instability in gastric fluid, the use of a sustained release
preparation may exacerbate gastric irritation and chemical
instability in gastric fluid. Drug absorption differences in
various gastrointestinal segments: In general, drug absorption is
moderately slow in the stomach, rapid in the small intestine, and
sharply declining in the large intestine. Compensation for changing
absorption characteristics in the gastrointestinal tract may be
important for some drugs. For example, it is rational for a
delivery system to pump out the drug much faster when the system
reaches the distal segment of the intestine, to avoid the
entombment of the drug in the feces.
Pulsed dose delivery systems, prepared as either single unit or
multiple unit formulations, and which are capable of releasing the
drug after a predetermined time, have been studied to address the
aforementioned problematic areas for sustained release
preparations. These same factors are also problematic in pulsed
dose formulations development. For example, gastrointestinal
transit times vary not only from patient to patient but also within
patients as a result of food intake, stress, and illness; thus a
single-unit pulsed-release system may give higher variability
compared to a multiple unit system. Additionally, drug layering or
core making for multiple unit systems is a time-consuming and
hard-to-optimize process. Particularly challenging for formulation
scientists has been overcoming two conflicting hurdles for
pulsatile formulation development, i.e., lag time and rapid
release.
Various enteric materials, e.g., cellulose acetate phtalate,
hydroxypropyl methylcellulose phtalate, polyvinyl acetate
phthalate, and the EUDRAGIT.RTM. acrylic polymers, have been used
as gastroresistant, enterosoluble coatings for single drug pulse
release in the intestine (3). The enteric materials, which are
soluble at higher pH values, are frequently used for colon-specific
delivery systems. Due to their pH-dependent attributes and the
uncertainty of gastric retention time, in-vivo performance as well
as inter- and intra-subject variability are major issues for using
enteric, coated systems as a time-controlled release of drugs.
A retarding swellable hydrophilic coating has been used for oral
delayed release systems (4,5). It was demonstrated that lag time
was linearly correlated with coating weight gain and drug release
was pH independent.
Hydroxypropyl methylcellulose barriers with erodible and/or
gellable characteristics formed using press coating technology for
tablet dosage forms have been described to achieve time-programmed
release of drugs (6). Barrier formulation variables, such as grade
of hydroxypropyl methylcellulose, water-soluble and water-insoluble
excipients, significantly altered the lag time and the release rate
from the center cores.
Special grades of hydroxypropyl methylcellulose, e.g.,
METHOLOSE.RTM. 60SH, 90SH (Shin-Etsu Ltd., Japan), and
METHOCEL.RTM. F4M (Dow Chemical Company, USA), as a hydrophilic
matrix material have been used to achieve bimodal drug release for
several drugs, i.e., aspirin, ibuprofen, and adinazolam (7).
Bimodal release is characterized by a rapid initial release,
followed by a period of constant release, and finalized by a second
rapid drug release.
Tablets or capsules coated with a hydrophobic wax-surfactant layer,
made from an aqueous dispersion of carnauba wax, beeswax,
polyoxyethylene sorbitan monooleate, and hydroxypropyl
methylcellulose have been used for rapid drug release after a
predetermined lag time. However, even though a two-hour lag time
was achieved for the model drug theophylline at a higher coating
level (60%), three hours were required for a complete release of
theophylline after the lag time. (8)
A sustained-release drug delivery system is described in U.S. Pat.
No. 4,871,549. When this system is placed into dissolution medium
or the gastrointestinal tract, water influx and the volume
expansion of the swelling agent cause the explosion of the water
permeable membrane. The drug thus releases after a predetermined
time period. The OROS.RTM. push-pull system (Alza Company) has been
developed for pulsatile delivery of water-soluble and
water-insoluble drugs (9,10), e.g. the OROS-CT.RTM. system and is
based on the swelling properties of an osmotic core compartment
which provides a pH-independent, time-controlled drug release.
The PULSINCAP.RTM. dosage form releases its drug content at either
a predetermined time or at a specific site (e.g., colon) in the
gastrointestinal tract (11). The drug formulation is contained
within a water-insoluble capsule body and is sealed with a hydrogel
plug. Upon oral administration, the capsule cap dissolves in the
gastric juice and the hydrogel plug swells. At a controlled and
predetermined time point, the swollen plug is ejected from the
PULSINCAP.RTM. dosage form and the encapsulated drug is released. A
pulsatile capsule system containing captopril with release after a
nominal 5-hr period was found to perform reproducibly in
dissolution and gamma scintigraphy studies. However, in the
majority of subjects, no measurable amounts of the drug were
observed in the blood, possibly due to instability of the drug in
the distal intestine. (12)
ADDERALL.RTM. comprises a mixture of four amphetamine salts,
dextroamphetamine sulfate, dextroamphetamine saccharate,
amphetamine asparate monohydrate and amphetamine sulfate, which in
combination, are indicated for treatment of Attention Deficity
Hyperactivity Disorder in children from 3-10 years of age. One
disadvantage of current treatment is that a tablet form is commonly
used which many young children have difficulty in swallowing.
Another disadvantage of current treatment is that two separate dose
are administered, one in the morning and one approximately 4-6
hours later, commonly away from home under other than parental
supervision. This current form of treatment, therefore, requires a
second treatment which is time-consuming, inconvenient and may be
problematic for those children having difficulty in swallowing
table formulations.
SUMMARY OF THE INVENTION
Accordingly, in view of a need for successfully administering a
multiple unit pulsed dose of amphetamine salts and mixtures
thereof, the present invention provides an oral multiple unit
pulsed dose delivery system for amphetamine salts and mixtures
thereof. FIG. 1 illustrates the desired target plasma level profile
of the pharmaceutical active contained within the delivery
system.
In accordance with a preferred embodiment of the present invention,
there is provided a pharmaceutical composition for delivering one
or more pharmaceutically active amphetamine salts that includes:
(a) one or more pharmaceutically active amphetamine salts that are
covered with an immediate release coating, and (b) one or more
pharmaceutically active amphetamine salts that are covered with an
enteric release coating wherein (1) the enteric release coating has
a defined minimum thickness and/or (2) there is a protective layer
between the at least one pharmaceutically active amphetamine salt
and the enteric release coating and/or (3) there is a protective
layer over the enteric release coating.
In one embodiment, the immediate release and enteric release
portions of the composition are present on the same core.
In another embodiment, the immediate release and enteric release
components are present on different cores.
It is also contemplated that the composition may include a
combination of the hereinabove referred to cores (one or more cores
that include both components on the same core and one or more cores
that include only one of the two components on the core).
The present invention provides a composition in which there is
immediate release of drug and enteric release of drug wherein the
enteric release is a pulsed release and wherein the drug includes
one or more amphetamine salts and mixtures thereof.
The immediate release component releases the pharmaceutical agent
in a pulsed dose upon oral administration of the delivery
system.
The enteric release coating layer retards or delays the release of
the pharmaceutical active or drug for a specified time period ("lag
time") until a predetermined time, at which time the release of the
drug is rapid and complete, i.e., the entire dose is released
within about 30-60 minutes under predetermined environmental
conditions, i.e. a particular location within the gastrointestinal
tract.
The delay or lag time will take into consideration factors such as
transit times, food effects, inflammatory bowel disease, use of
antacids or other medicaments which alter the pH of the GI
tract.
In a preferred embodiment, the lag time period is only
time-dependent, i.e., pH independent. The lag time is preferably
within 4 to 6 hours after oral administration of the delivery
system.
In one aspect, the present invention is directed to a composition
that provides for enteric release of at least one pharmaceutically
active amphetamine salt, including at least one pharmaceutically
active amphetamine salt that is coated with an enteric coating
wherein (1) the enteric release coating has a defined minimum
thickness and/or (2) there is a protective layer between the at
least one pharmaceutically active amphetamine salt and the enteric
release coating and/or (3) there is a protective layer over the
enteric release coating.
In attempting to provide for enteric release of an amphetamine
salt, applicants found that use of an enteric release coating as
generally practiced in the art did not provide effective enteric
release.
Typical enteric coating levels did not meet the above requirements
for the desired dosage profile of amphetamine salts. Using the
typical amount of enteric coating (10-20.mu.) resulted in undesired
premature leakage of the drug from the delivery system into the
upper gastrointestinal tract and thus no drug delivery at the
desired location in the gastrointestinal tract after the
appropriate lag time. Thus this coating did not meet the
requirements for the drug release profile to provide full
beneficial therapeutic activity at the desired time.
Surprisingly, applicants found that using a thicker application of
enteric coating on the formulation allowed for the second pulsed
dose to be released only and completely at the appropriate time in
the desired predetermined area of the gastrointestinal tract, i.e.,
in the intestine.
This was surprising because an increase in thickness of about
5-10.mu. of enteric coatings above a minimum thickness of about
10-20.mu. typically does not have a significant effect on release
of drug from within such coatings. Enteric coatings typically are
pH dependent and will only dissolve/disperse when exposed to the
appropriate environment. Typically, application of a thicker
coating (greater than 20.mu.) will only marginally increase the
time for complete release at the appropriate environmental
condition i.e., for a brief period of time (20 minutes). Using the
typical coating, applicants could not achieve the desired
result--rather, the coating leaked before the predetermined time in
an inappropriate environment resulting in significant loss of the
therapeutic agent.
Accordingly, in one aspect, the pulsed enteric release of the
amphetamine salts is accomplished by employing a certain minimum
thickness of the enteric coating.
In one embodiment of the invention, the pulsed dose delivery
comprises a composition which comprises one or more
pharmaceutically active amphetamine salts; an enteric coating over
the one or more pharmaceutically active amphetamine salts, wherein
the thickness of the enteric coating layer is at least 25.mu.; a
further layer of one or more pharmaceutically active amphetamine
salts over the enteric coating layer; and an immediate release
layer coating. The thicker enteric coating surprisingly provides
the required delayed immediate release of the pharmaceutically
active amphetamine salt at the desired time in the desired area of
the gastrointestinal tract. FIG. 2 illustrates a model of this
delivery system.
In this aspect, the one or more pharmaceutically active amphetamine
salts can be provided within or as a part of a core seed around
which the enteric coating is applied. Alternatively, a core seed
can be coated with one or more layers of one or more
pharmaceutically active amphetamine salts.
It has further been discovered that a delayed immediate release
drug delivery can also be accomplished by coating the drug first
with a protective layer prior to applying the enteric coating.
Thus, in another embodiment, the pulsed enteric release is
accomplished by employing a protective layer between the drug and
the enteric coating. When using a protective coating, the enteric
coating may be of an increased thickness or may be of lower
thickness.
Thus, in another aspect, the object of the invention is met by
providing a composition comprising one or more pharmaceutically
active amphetamine salts; a protective layer coating over the one
or more pharmaceutically active amphetamine salt layer(s), and an
enteric coating layer over the protective coating layer; a further
pharmaceutically active amphetamine salt layer and an immediate
release layer coating. In a preferred embodiment of this aspect,
the thickness of the enteric coating is at least 25.mu., and the
protective layer comprises an immediate release coating.
With respect to this embodiment of the invention, the one or more
pharmaceutically active amphetamine salts can be provided within or
as a part of a core seed, during the core seed manufacturing
process, around which the protective coating is applied.
Alternatively, a core seed can be coated with one or more layers of
one or more pharmaceutically active amphetamine salts.
In another embodiment, the pulsed enteric release is accomplished
by employing a protective layer over the enteric coating.
Accordingly, in this embodiment of the present invention, there is
provided a pulsed dose release drug delivery system comprising one
or more pharmaceutically active amphetamine salts; an enteric
coating layer over the pharmaceutically active amphetamine salt
layer(s); and a protective layer over the enteric coating; a second
pharmaceutically active amphetamine salt layer; and an immediate
release layer coating.
In one aspect of this embodiment, the protective layer is comprised
of one or more components, which includes an immediate release
layer and a modifying layer. The modifying layer is preferably
comprised of a semi water-permeable polymer. Applicants have
surprisingly found that a semi-permeable polymer coating used in
combination with an immediate release layer coating provided a
delayed pulsed release drug delivery profile when layered over the
enteric coating.
Thus, in this embodiment, the protective layer comprises a
semi-permeable polymer and an immediate release coating layer. In a
preferred embodiment, the modifying layer comprises a first layer
of a semi-permeable polymer which is adjacent to the enteric
coating layer and a second coating layer over the semi-permeable
polymer coating layer comprising an immediate release polymer
coating layer.
In one aspect of this embodiment, a semi-permeable polymer, which
may comprise a low water-permeable pH-insensitive polymer, is
layered onto the outer surface of the enteric layer, in order to
obtain prolonged delayed release time. This semi-permeable polymer
coating controls the erosion of the pH-sensitive enteric polymer in
an alkaline pH environment in which a pH-sensitive polymer will
dissolve rapidly. Another pH-sensitive layer may be applied onto
the surface of a low water-permeability layer to further delay the
release time.
In a still further aspect of the invention, in addition to a
protective layer, the composition comprises an acid which is
incorporated into the pharmaceutical active layer or coated onto
the surface of the active layer to reduce the pH value of the
environment around the enteric polymer layer. The acid layer may
also be applied on the outer layer of the pH-sensitive enteric
polymer layer, followed by a layer of low water-permeability
polymer. The release of the active thus may be delayed and the
dissolution rate may be increased in an alkaline environment.
In a further embodiment, the protective coating may be used both
over the drug and over the enteric coating.
With respect of this embodiment of the invention, the one or more
pharmaceutically active amphetamine salts can be provided within or
as a part of a core seed, during the core seed manufacturing
process, around which the enteric coating is applied.
Alternatively, a core seed can be coated with one or more layers of
one or more pharmaceutically active amphetamine salts.
The drug delivery system of the present invention as described
herein preferably comprises one or a number of beads or beadlets in
a dosage form, either capsule, tablet, sachet or other method of
orally administering the beads.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 illustrates a multiple pulse drug delivery system target
plasma profile of the drug delivery system of the present
invention. The profile reflects an immediate-release component
followed by a delayed-release component.
FIG. 2a graphically illustrates a pulsed dose delivery system.
FIGS. 2b and c graphically illustrate the drug release mechanism
from the proposed delivery system.
FIG. 3 is a plot of the present drug released versus time from the
drug-loaded pellets described in Example 1 which exemplifies the
immediate release component of the present invention.
FIG. 4 is a plot of the percent drug released versus time from the
coated pellets described in Example 2 which exemplifies .[.the
immediate release component and.]. the delayed release components
of the present invention.
FIG. 5 is a plot of the percent drug released versus time from the
coated pellets described in Example 3 which exemplifies .[.the
immediate release component and.]. the delayed release components
of the present invention.
FIG. 6 illustrates the drug release profile of coated pellets
described in Example 4 which exemplifies .[.the immediate release
component and.]. the delayed release components of the present
invention.
FIG. 7 is a plot of a profile of plasma amphetamine concentration
after administration of a composite capsule containing the
immediate release pellets and delayed release pellets from Examples
1 and 2, respectively.
FIG. 8 is a plot of a profile of plasma amphetamine concentration
after administration of a composite capsule containing the
immediate release pellets and delayed release pellets from Examples
1 and 3, respectively.
DETAILED DESCRIPTION OF THE INVENTION
The present invention comprises a core or starting seed, either
prepared or commercially available product. The cores or starting
seeds can be sugar spheres; spheres made from microcrystalline
cellulose and any suitable drug crystals.
The materials that can be employed in making drug-containing
pellets are any of those commonly used in pharmaceutics and should
be selected on the basis of compatibility with the active drug and
the physicochemical properties of the pellets. The additives except
active drugs are chosen below as examples.
Binders such as cellulose derivatives such as methylcellulose,
hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl
methylcellulose, polyvinylpyrrolidone, polyvinylpyrrolidone/vinyl
acetate copolymer and the like.
Disintegration agents such as corn starch, pregelatinized starch,
cross-linked carboxymethylcellulose (AC-DI-SOL.RTM.), sodium starch
glycolate (EXPLOTAB.RTM.), cross-linked polyvinylpyrrolidone
(PLASDONE XL.RTM.), and any disintegration agents used in tablet
preparations.
Filling agents such as lactose, calcium carbonate, calcium
phosphate, calcium sulfate, microcrystalline cellulose, dextran,
starches, sucrose, xylitol, lactitol, mannitol, sorbitol, sodium
chloride, polyethylene glycol, and the like.
Surfactants such as sodium lauryl sulfate, sorbitan monooleate,
polyoxyethylene sorbitan monooleate, bile salts, glyceryl
monostearate, PLURONIC.RTM. line (BASF), and the like.
Solubilizers such as citric acid, succinic acid, fumaric acid,
malic acid, tartaric acid, maleic acid, glutaric acid sodium
bicarbonate and sodium carbonate and the like.
Stabilizers such as any antioxidation agents, buffers, acids, and
the like, can also be utilized.
Methods of manufacturing the core include a.
Extrusion-Spheronization--Drug(s) and other additives are
granulated by addition of a binder solution. The wet mass is passed
through an extruder equipped with a certain size screen. The
extrudates are spheronized in a marumerizer. The resulting pellets
are dried and sieved for further applications. b. High-Shear
Granulation--Drug(s) and other additives are dry-mixed and then the
mixture is wetted by addition of a binder solution in a high
shear-granulator/mixer. The granules are kneaded after wetting by
the combined actions of mixing and milling. The resulting granules
or pellets are dried and sieved for further applications. c.
Solution or Suspension Layering--A drug solution or dispersion with
or without a binder is sprayed onto starting seeds with a certain
particle size in a fluid bed processor or other suitable equipment.
The drug thus is coated on the surface of the starting seeds. The
drug-loaded pellets are dried for further applications.
For purposes of the present invention, the core particles have a
diameter in the range of about 50-1500 microns; preferably 100-800
microns.
These particles can then be coated in a fluidized bed apparatus
with an alternating sequence of coating layers.
The core may be coated directly with a layer or layers of at least
one pharmaceutically active amphetamine salts and/or the
pharmaceutically active amphetamine salt may be incorporated into
the core material. Pharmaceutical active amphetamine salts
contemplated to be within the scope of the present invention
include amphetamine base, all chemical and chiral derivatives and
salts thereof; methylphenidate, all chemical and chiral derivatives
and salts thereof; phenylpropanolamine and its salts; and all other
compounds indicated for the treatment of attention deficit
hyperactivity disorder (ADHD).
A protective layer may be added on top of the pharmaceutical active
containing layer and also may be provided between active layers. A
separation or protective layer may be added onto the surface of the
active-loaded core, and then the enteric layer is coated thereupon.
Another active layer may also be added to the enteric layer to
deliver an initial dose.
A protective coating layer may be applied immediately outside the
core, either a drug-containing core or a drug-layered core, by
conventional coating techniques such as pan coating or fluid bed
coating using solutions of polymers in water or suitable organic
solvents or by using aqueous polymer dispersions. Suitable
materials for the protective layer include cellulose derivatives
such as hydroxyethyl cellulose, hydroxypropyl cellulose,
hydroxypropyl methylcellulose, polyvinylpyrrolidone,
polyvinylpyrrolidone/vinyl acetate copolymer, ethyl cellulose
aqueous dispersions (AQUACOAT.RTM., SURELEASE.RTM.), EUDRAGIT.RTM.
RL 30D, OPADRY.RTM. and the like. The suggested coating levels are
from 1 to 6%, preferably 2-4% (w/w).
The enteric coating layer is applied onto the cores with or without
seal coating by conventional coating techniques, such as pan
coating or fluid bed coating using solutions of polymers in water
or suitable organic solvents or by using aqueous polymer
dispersions. All commercially available pH-sensitive polymers are
included. The pharmaceutical active is not released in the acidic
stomach environment of approximately below pH 4.5, but not limited
to this value. The pharmaceutical active should become available
when the pH-sensitive layer dissolves at the greater pH, after a
certain delayed time; or after the unit passes through the stomach.
The preferred delay time is in the range of two to six hours.
Enteric polymers include cellulose acetate phthalate, Cellulose
acetate trimellitate, hydroxypropyl methylcellulose phtalate,
polyvinyl acetate phtalate, carboxymethylethylcellulose,
co-polymerized methacrylic acid/methacrylic acid methyl esters such
as, for instance, materials known under the trade name
EUDRAGIT.RTM. L12.5, L100, or EUDRAGIT.RTM. S12.5, S100 or similar
compounds used to obtain enteric coatings. Aqueous collodial
polymer dispersions or re-dispersions can be also applied, e.g.
EUDRAGIT.RTM. L 30D-55, EUDRAGIT.RTM. L100-55, EUDRAGIT.RTM. S100,
EUDRAGIT.RTM. preparation 4110D (Rohm Pharma); AQUATERIC.RTM.,
AQUACOAT.RTM. CPD 30 (FMC); KOLLICOAT MAE.RTM. 30D and 30DP (BASF);
EASTACRYL.RTM. 30D (Eastman Chemical).
The enteric polymers used in this invention can be modified by
mixing with other known coating products that are not pH sensitive.
Examples of such coating pro ducts include the neutral methacrylic
acid esters with a small portion of trimethylammonioethyl
methacrylate chloride, sold currently under the trade names
EUDRAGIT.RTM. RS and EUDRAGIT.RTM. RL; a neutral ester dispersion
without any functional groups, sold under the trade names
EUDRAGIT.RTM. NE30D; and other pH independent coating products.
The modifying component of the protective layer used over the
enteric coating can include a water penetration barrier layer
(semipermeable polymer) which can be successively coated after the
enteric coating to reduce the water penetration rate through the
enteric coating layer and thus increase the lag time of the drug
release. Sustained-release coatings commonly known to one skilled
in the art can be used for this purpose by conventional coating
techniques such as pan coating or fluid bed coating using solutions
of polymers in water or suitable organic solvents or by using
aqueous polymer dispersions. For example, the following materials
can be used, but not limited to: Cellulose acetate, Cellulose
acetate butyrate, Cellulose acetate propionate, Ethyl cellulose,
Fatty acids and their esters, Waxes, zein, and aqueous polymer
dispersions such as EUDRAGIT.RTM. RS and SURELEASE.RTM., cellulose
acetate latex. The combination of above polymers and hydrophilic
polymers such as Hydroxyethyl cellulose, Hydroxypropyl cellulose
(KLUCEL.RTM., Hercules Corp.), Hydroxypropyl methylcellulose
(METHOCEL.RTM., Dow Chemical Corp.), Polyvinylpyrrolidone can also
be used.
An overcoating layer can further optionally be applied to the
composition of the present invention. OPADRY.RTM., OPADRY II.RTM.
(Colorcon) and corresponding color and colorless grades from
Colorcon can be used to protect the pellets from being tacky and
provide colors to the product. The suggested levels of protective
or color coating are from 1 to 6%, preferably 2-3% (w/w).
Many ingredients can be incorporated into the overcoating formula,
for example to provide a quicker immediate release, such as
plasticizers: acetyltriethyl citrate, triethyl citrate,
acetyltributyl citrate; dibutylsebacate, triacetin, polyethylene
glycols, propylene glycol and the others; lubricants: talc,
colloidal silica dioxide, magnesium stearate, calcium stearate,
titanium dioxide, magnesium silicate, and the like.
The composition, preferably in beadlet form, can be incorporated
into hard gelatin capsules, either with additional excipients, or
alone. Typical excipients to be added to a capsule formulation
include, but are not limited to: filters such as microcrystalline
cellulose, soy polysaccharides, calcium phosphate dihydrate,
calcium sulfate, lactose, sucrose, sorbitol, or any other inert
filler. In addition, there can be flow aids such as fumed silicon
dioxide, silica gel, magnesium stearate, calcium stearate or any
other material imparting flow to powders. A lubricant can further
be added if necessary by using polyethylene glycol, leucine,
glyceryl behenate, magnesium stearate or calcium stearate.
The composition may also be incorporated into a tablet, in
particular by incorporation into a tablet matrix, which rapidly
disperses the particles after ingestion. In order to incorporate
these particles into such a tablet, a filler/binder must be added
to a table that can accept the particles, but will not allow their
destruction during the tableting process. Materials that are
suitable for this purpose include, but are not limited to,
microcrystalline cellulose (AVICEL.RTM.), soy polysaccharide
(EMCOSOY.RTM.), pre-gelatinized starches (STARCH.RTM. 1500,
NATIONAL.RTM. 1551), and polyethylene glycols (CARBOWAX.RTM.). The
materials should be present in the range of 5-75% (w/w), with a
preferred range of 25-50% (w/w).
In addition, disintegrants are added in order to dispense the beads
once the tablet is ingested. Suitable disintegrants include, but
are not limited to: cross-linked sodium carboxymethyl cellulose
(AC-DI-SOL.RTM.), sodium starch glycolate (EXPLOTAB.RTM.,
PRIMOJEL.RTM.), and cross-linked polyvinylpolypyrrolidone
(Plasone-XL). These materials should be present in the rate of
3-15% (w/w), with a preferred range of 5-10% (w/w).
Lubricants are also added to assure proper tableting, and these can
include, but are not limited to: magnesium stearate, calcium
stearate, stearic acid, polyethylene glycol, leucine, glyceryl
behanate, and hydrogenated vegetable oil. These lubricants should
be present in amounts from 0.1-10% (w/w), with a preferred range of
0.3-3.0% (w/w).
Tablets are formed, for example, as follows. The particles are
introduced into a blender along with AVICEL.RTM., disintegrants and
lubricant, mixed for a set number of minutes to provide a
homogeneous blend which is then put in the hopper of a tablet press
with which tablets are compressed. The compression force used is
adequate to form a tablet; however, not sufficient to fracture the
beads or coatings.
It will be appreciated that the multiple dosage form of the present
invention can deliver rapid and complete dosages of
pharmaceutically active amphetamine salts to achieve the desired
levels of the drug in a recipient over the course of about 8 hours
with a single oral administration.
In so doing, the levels of drug in blood plasma of the
pharmaceutically active amphetamine salts will reach a peak fairly
rapidly after about 2 hours, and after about 4 hours a second pulse
dose is released, wherein a second fairly rapid additive increase
of plasma drug levels occurs which slowly decreases over the course
of the next 12 hours.
The following examples are presented to illustrate and do not limit
the invention.
EXAMPLES
Example 1
Immediate Release Formulation
The following formulation was used to layer the drug onto sugar
spheres. Nonpareil seeds (30/35 mesh, Paulaur Corp., NJ), 6.8 kg
were put into a FLM-15 fluid bed processor with a 9'' Wurster
column and fluidized at 60.degree. C. The suspension of mixed
amphetamine salts (MAS) with 1% HPMC E5 Premium (Dow Chemical) as a
binder was sprayed onto the seed under suitable conditions. Almost
no agglomeration and no fines were observed with a yield of at
least 98%. The drug-loaded cores were used to test enteric coatings
and sustained release coatings.
TABLE-US-00001 TABLE 1 Ingredients Amount (%) Nonpareil seed 88.00
mixed amphetamine salts 11.40 METHOCEL .RTM. E5 Premium 0.60 Water
* *removed during processing
The drug release profile of the drug-loaded pellets of this example
is shown in FIG. 3.
Example 2
The following formulation was used to coat the mixed amphetamine
salts loaded (MASL) pellets from Example 1 with the EUDRAGIT.RTM. L
30D-55 (Rohm Pharma, Germany) coating dispersion. 2 kg of MASL
pellets were loaded into a fluid bed processor with a reduced
Wurster column equipped with a precision coater .[.(MP 2/3, Niro
Inc).]. (.Iadd.see Examples 3 and 4.Iaddend.). The coating
dispersion was prepared by dispersing Triethyl citrate, Talc and
EUDRAGIT.RTM. L 30D-55 into water and mixing for at least 30
minutes. Under suitable fluidization conditions, the coating
dispersion was sprayed onto the fluidized MASL pellets. The
spraying was continued until the targeted coating level was
achieved .[.(20 .mu.).]. . The coated pellets were dried at
30-35.degree. C. for 5 minutes before stopping the process. The
enteric coated .[.PPA.]. .Iadd.MASL .Iaddend.pellets were tested at
different pH buffers by a USP paddle method. The drug content was
analyzed using HPLC. The results showed that the enteric coating
delayed the drug release from the coated pellets until after
exposure to pH 6 or higher. (Reference #AR98125-4)
TABLE-US-00002 TABLE 2 Ingredients Amount (%) MASL pellets
.[.40.00.]. .Iadd.70.00.Iaddend. EUDRAGIT .RTM. L 30D-55 24.88
Triethyl citrate 2.52 Talc 2.60 Water * *removed during
processing
The drug release profile of the coated pellets of this example is
shown in FIG. 4.
Example 3
The following formulation was used to coat the MASL pellets from
Example 1 with the EUDRAGIT.RTM. 4110D (Rohm Pharma, Germany)
coating dispersion. MASL pellets (2 kg) were loaded in a fluid bed
processor with a reduced Wurster column (GPGC-15, Glatt). The
coating dispersion was prepared by dispersing Triethyl citrate,
Talc and EUDRAGIT.RTM. 4110D into water and mixing for at least 30
minutes. Under suitable fluidization conditions, the coating
dispersion was sprayed onto the fluidized MASL pellets. The
spraying was continued until the targeted coating level was
achieved. The coated pellets were dried at 30-35.degree. C. for 5
minutes before stopping the process. The enteric coated MASL
pellets were tested using a USP paddle method at different pH
buffers. The drug content was analyzed using HPLC. The enteric
coating delayed the drug release for several hours from the coated
pellets until the pH value reached 6.8 or higher, as shown below in
Table 3. (Reference #AR98125-3)
TABLE-US-00003 TABLE 3 Ingredients Amount (%) MASL pellets
.[.70.00.]. EUDRAGIT .RTM. 4110D .[.26.24.]. Triethyl citrate
.[.0.76.]. Talc .[.3.00.]. Water * *removed during processing
The drug release profile of coated pellets of this example is shown
in FIG. 5.
Example 4
The following formulation was selected to coat the enteric coated
MASL pellets. Coated MASL pellets from Example 2 or coated MASL
pellets from Example 3 (2 kg of either) were loaded into a fluid
bed processor with a reduced Wurster column (GPGC-15, Glatt). The
coating dispersion was prepared by mixing SURELEASE.RTM. (Colorcon)
and water for at least 15 minutes prior to spraying. Under suitable
fluidization conditions, the coating dispersion was sprayed onto
the fluidizated pellets. The spraying was continued until the
targeted coating level was achieved. The coated pellets were coated
with a thin layer of OPADRY.RTM. white (Colorcon) (2%) to prevent
the tackiness of the coated pellets during storage. The coated
pellets were then dried at 35-40.degree. C. for 10 minutes before
discharging from the bed. The drug dissolution from both coated
pellets was performed using a USP paddle method at different pH
buffers. The drug content was analyzed using HPLC. The 8%
SURELEASE.RTM. coating slightly sustained the drug release from
EUDRAGIT.RTM. L 30D-55 coated pellets at pH 7.5 buffer, while the
SURELEASE.RTM. coating delayed the drug release up to 2 hours after
the buffer switched from pH 1 to pH 7.5. (Reference
##AR98125-1)
TABLE-US-00004 TABLE 4 Ingredients Amount, (%) Enteric coated MASL
pellets 90.00 SURELEASE .RTM. 8.00 OPADRY .RTM. white 2.00 Water *
*removed during processing
The drug release profile of the coated pellets from this example is
shown in FIG. 6.
Example 5
A pulsatile delivery system can be achieved by combining the
immediate release pellets (Example 1) with delayed release pellets
(Example 2 or Example 3). The immediate-release pellets equivalent
to half the dose and the delayed-release pellets equivalent to half
the dose are filled into a hard gelatin capsule to produce the oral
pulsed dose delivery system. The delayed-release portion releases
the amphetamine salts rapidly and completely, after a specified lag
time. The capsule products containing immediate-release pellets and
delayed-release pellets (Example 1 plus Example 2 and Example 1
plus Example 3) were tested in a crossover human study. FIGS. 7 and
8 show the typical profiles of plasma amphetamine concentration
after administration of a composite capsule containing the
immediate-release pellets and delayed-release pellets from Examples
1 and 2 (10 mg dose each pellet type) and a capsule containing the
pellets from immediate-release pellets and delayed-release pellets
from Examples 1 and 3 (10 mg dose each pellet type), respectively.
The general plasma profiles are similar to the desired target
plasma level profile shown in FIG. 1.
It is to be understood, however, that the scope of the present
invention is not to be limited to the specific embodiments
described above. The invention may be practiced other than as
particularly described and still be within the scope of the
accompanying claims.
CITED LITERATURE
1. B. Lemmer, "Circadian Rhythms and Drug Delivery", J. Controlled
Release, 16, 63-74 (1991) 2. B. Lemmer, "Why are so may Biological
Systems Periodic?" in Pulsatile Drug Delivery: Current Applications
and Future Trends, R Gurny, H E Junginger and N A Peppas, eds.
(Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, Germany 1993)
pp.11-24 3. X. Xu and P I Lee, "Programmable Drug Delivery from an
Erodible Association Polymer System", Pharm. Res. 10(8), 1144-1152
(1993) 4. A. Gazzaniga, M E Sangalli, and F Giodano, "Oral
Chonotropic Drug Delivery Systems: Achievement of Time and/or Site
Specificity", Eur J. Pharm. Biopharm., 40(4), 246-250 (1994) 5. A
Gazzaniga, C Busetti, L Moro, M E Sangalli and F Giordano, "Time
Dependent Oral Delivery Systems for Colon Targeting", S.T.P. Pharma
Sciences 5(1), 83-88 (1996) 6. U Conte, L Maggi, M L Torre, P
Giunchedi and A Lamanna, "Press-coated Tablets for Time programmed
Release of Drugs", Biomaterials, 14(13), 1017-1023 (1993) 7. A C
Shah International Patent Application WO87/00044 8. P S Walia, P Jo
Mayer Stout and R Turton, "Preliminary Evaluation of an Aqueous Wax
Emulsion for Controlled Release Coating",Pharm Dev Tech, 3(1),
103-113 (1998) 9. F Theeuwes, "OROS.RTM. Osmotic System
Development", Drug Dev Ind Pharm 9(7), 1331-1357 (1983) 10. F
Theeuwes, "Triggered Pulsed and Programmed Drug Delivery" in Novel
Drug Delivery and its Therapeutic Application, L F Prescott and W S
Nimmos, eds (Wiley, New York, 1989) pp.323-340 11. M McNeil, A
Rashid and H Stevens, International Patent App WO90/09168 12. I R
Wilding, S S Davis, M Bakhshaee, H N E Stevens, R A Sparrow and J
Brennan, "Gastrointestinal Transit and Systemic Absorption of
Captopril from a Pulsed Release Formulation", Pharm Res 9(5),
654-657 (1992)
* * * * *